![Enterome initiates first clinical trial with EO2401 – an innovative microbiomeantigen based cancer immunotherapy candidate targeting aggressive brain cancer](https://www.seventure.fr/wp-content/uploads/2020/07/10_104270789-322x211.jpg)
Enterome initiates first clinical trial with EO2401 – an innovative microbiomeantigen based cancer immunotherapy candidate targeting aggressive brain cancer
ENTEROME SA, a clinical-stage biopharmaceutical company leveraging its unique knowledge of the microbiome-immunoinflammation axis to develop next-generation therapeutics,...